Insulia

By Dave Muoio November 29, 2017
A slew of digital diabetes care companies have announced integrations with the upcoming virtual Type 2 diabetes management platform being developed by Onduo, a joint venture of Verily and Sanofi. These announced services include Voluntis’ Insulia, a digital insulin dose recommendation and coaching system; Glytec’s Glucommander Outpatient, cloud-based software that evaluates blood glucose and...
By Jonah Comstock November 16, 2017
Medical device software company Voluntis has received an updated FDA clearance (as well as an updated CE mark) for its Insulia app, a "digital companion" app for people with Type 2 diabetes. Insulia offers realtime basal insulin dose coaching, and the new clearance makes the app usable with two additional brands of insulin: Basaglar and Tresiba. The app had already worked for users of Lantus,...
By Heather Mack February 16, 2017
App-based doctor house call company Pager will incorporate PokitDok’s healthcare price comparison tool into its care navigation platform. In addition to the ability to find board-certified doctors, registered nurses, physician assistants and nurse practitioners and arrange either in-home or telemedicine visits (or refer to a specialist) Pager customers will also be able to verify insurance or...
By Heather Mack February 16, 2017
Chronic disease management company Livongo is collaborating with Voluntis, the Paris, France-based company that develops companion apps for medical devices, to offer an integrated program, insulin delivery system and app for people with type 2 diabetes. Members will have access to the Livongo for Diabetes Program with Voluntis’ Insulia, the diabetes management app that received both FDA approval...
By Heather Mack December 6, 2016
Paris, France and Cambridge, Massachusetts-based Voluntis, which makes companion software for medical devices or medications, has received both FDA clearance and the CE Mark for a type 2 diabetes management app called Insulia. The app, which is designed for people treated with basal insulin, is classified as a prescription-only medical device and will be available to patients and healthcare...